Oncopeptides AB: Developing Melflufen (Ygalo): alkylating peptide in class of Peptidase Enhanced Compounds targeting MM transformation process, selectively targets MM. Accelerated approval filing planned H1'20 based on ongoing Ph2 Horizon. MoA overcomes resistance mechanisms for current therapies (iMIDs), demonstrated superior efficacy vs. SOC. Presented interim data at ASH (2019) from ongoing Ph2 HORIZON study in late stage r/r MM showing ORR of ~32%. Ph 3 OCEAN study comparing Ygalo to pomalidomide in late-stage r/r MM, Ph 1/2 ANCHOR study in combo w bortezomib or daratumumab in r/r MM.
Based in...
Clinical Stage
Phase III
Disease Space
Hematology, Oncology
Europe, Public
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
Västra Trädgårdsgatan 15
Stockholm, SE-111 53

Top 10 Holders of Oncopeptides AB

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
C Worldwide Asset Management Fondsmæglerselskab A/S (Sweden) 5.93 3,201,596 46.63 Stakes 7/13/20
Fjärde AP-fonden 5.93 3,200,000 46.61 Stakes 7/31/20
Max Mitteregger Kapitalförvaltning AB 5.93 3,200,000 46.61 Stakes 3/31/20
Swedbank Robur Fonder AB 5.20 2,807,502 40.89 Stakes 4/9/20
Handelsbanken Fonder AB 4.13 2,797,762 40.75 Stakes 11/7/19
Invesco Advisers, Inc. 3.71 2,000,000 29.13 Stakes 3/31/20
AFA Sjukförsäkringsaktiebolag (Invt Mgmt) 2.79 1,507,554 21.96 Stakes 3/31/20
AMF Fonder AB 1.98 1,070,452 15.59 Stakes 3/31/20
Andra AP-fonden 1.52 820,717 11.95 Stakes 3/31/20
Norron AB 1.11 600,562 8.75 Funds 8/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.